Literature DB >> 2432895

Growth inhibitory effects of 5-aza-2'-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction.

A Levva, G Schwartsmann, L C Boeije, H M Pinedo, F de Waal.   

Abstract

In the original HL-60 cells (HL-60-S) and an HL-60 subline (HL-60-R) respectively susceptible and resistant to induction of differentiation by retinoic acid or dimethyl sulfoxide, 5-aza-2'-deoxycytidine inhibited growth equally but induced differentiation to a greater extent in HL-60-S. Flow cytometry showed that 5-aza-2'-deoxycytidine produced in both HL-60 lines an increased proportion of cells in G2+M rather than G0/G1 as with retinoic acid. 5-aza-2'-deoxycytidine may have a differentiation-inducing effect in HL-60 provided cells have the competence to differentiate, indicating the importance of an alternate mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2432895     DOI: 10.1016/s0006-291x(86)80219-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

Authors:  G Schwartsmann; H Schunemann; C N Gorini; A F Filho; C Garbino; G Sabini; I Muse; L DiLeone; D R Mans
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Preclinical antitumor activity of 5-aza-2'-deoxycytidine against human and neck cancer xenografts [corrected].

Authors:  B J Braakhuis; G A van Dongen; M van Walsum; A Leyva; G B Snow
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

3.  The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation.

Authors:  Ruth Meier; Gabriele Greve; Dennis Zimmer; Helena Bresser; Bettina Berberich; Ralitsa Langova; Julia Stomper; Anne Rubarth; Lars Feuerbach; Daniel B Lipka; Joschka Hey; Björn Grüning; Benedikt Brors; Justus Duyster; Christoph Plass; Heiko Becker; Michael Lübbert
Journal:  Blood Cancer J       Date:  2022-08-22       Impact factor: 9.812

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.